钙网蛋白(calreticulin,CRT)是参与多种细胞过程的高度保守的内质网伴侣蛋白。1974年,它首次被鉴定为钙离子结合蛋白,随后CRT与肿瘤之间信号通路相关关系被广泛的研究。另外,在人类多种肿瘤中,细胞表面的CRT被认为是1个“促吞噬”信号,由此CRT与癌细胞的巨噬细胞吞噬免疫系统的相关研究,有望为肿瘤综合治疗提供新的理论依据和策略。也有越来越多的证据表明CRT在不同肿瘤中的异常表达,将为CRT成为一种新的肿瘤标志物提供许多依据。以及CRT对各种肿瘤的发展具有很重要的影响且CRT对肿瘤形成和进展的影响取决于细胞类型和临床阶段。 Calreticulin (CRT) is a highly conserved endoplasmic reticulum chaperone protein involved in many cellular processes. It was first identified as a calcium-binding protein in 1974, and then the relationship between CRT and tumor signaling was extensively studied. In addition, a variety of human tumors, the cell surface of the CRT is considered to be a “phagocytosis” signal, which CRT and macrophages of cancer cells phagocytosis immune system is expected to provide new treatment for cancer Theoretical basis and strategy. There is also increasing evidence that the abnormal expression of CRT in different tumors will provide many bases for CRT to become a new tumor marker. And CRT have a significant impact on the development of various tumors and the impact of CRT on tumor formation and progression depends on the cell type and clinical stage.